Clinical trial NCT05152147: A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
Official title: A Randomized, Multicenter, Phase 3 Study of Zanidatamab in Combination With Chemotherapy With or Without Tislelizumab in Subjects With HER2-positive Unresectable Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma (GEA)
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE3
Conditions: Gastric Neoplasms
Gastroesophageal Adenocarcinoma
Esophageal Adenocarcinoma
Keywords: HER2
Bispecific antibody
Biparatopic antibody
Immunotherapy
Gastric cancers
Esophageal cancers
Chemotherapy
FP
Capecitabine
Cisplatin
5-FU
Oxaliplatin
Gastroesophageal adenocarcinoma
CAPOX
Programmed cell death receptor 1 (PD-1)
Anti-PD-1
Anti PD-1
JZP598
Lead sponsor: Jazz Pharmaceuticals
Sponsor class: INDUSTRY
Collaborators: name: BeiGene
First posted: 2021-12-09
Enrollment: 920
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: multi-cohort, open-label, multicenter study
Primary purpose: TREATMENT

Brief summary: This study is being done to find out if zanidatamab, when given with chemotherapy plus or minus tislelizumab, is safe and works better than trastuzumab given with chemotherapy.

The patients in this study will have advanced human epidermal growth factor 2 (HER2)-positive stomach and esophageal cancers that are no longer treatable with surgery (unresectable) or chemoradiation, and/or have grown or spread to other parts of the body (metastatic).


Eligibility criteria: Inclusion Criteria:

* Histologically confirmed unresectable locally advanced, recurrent or metastatic HER2-positive gastroesophageal adenocarcinoma (adenocarcinomas of the stomach or esophagus, including the gastroesophageal junction), defined as 3+ HER2 expression by IHC or 2+ HER2 expression by IHC with ISH positivity per central assessment. Subjects with esophageal adenocarcinoma must not be eligible for combined chemoradiotherapy at the time of enrollment
* Assessable (measurable or non-measurable) disease as defined by RECIST 1.1
* Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1, assessed within 3 days prior to randomization
* Adequate organ function
* Left ventricular ejection fraction (LVEF) ≥ 50% as determined by either echocardiogram or multiple gated acquisition scan (MUGA)

Exclusion Criteria:

* Prior treatment with a HER2-targeted agent, with the exception of subjects who received HER2-targeted treatment for breast cancer \> 5 years prior to initial diagnosis of GEA
* Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2 or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
* Prior treatment with systemic antineoplastic therapy or intraperitoneal chemotherapy for unresectable locally advanced, recurrent or metastatic GEA
* Untreated central nervous system (CNS) metastases, symptomatic CNS metastases, or radiation treatment for CNS metastases within 4 weeks prior to randomization. Stable, treated brain metastases are allowed (defined as subjects who are completely off steroids and anticonvulsants and are neurologically stable with no evidence of radiographic progression for at least 4 weeks prior to randomization)
* Known history of or ongoing leptomeningeal disease (LMD)
* Known additional malignancy that is not considered cured or that has required treatment within the past 3 years
* Known active hepatitis
* Any history of human immunodeficiency virus (HIV) infection
* Known SARS-CoV-2 infection; subjects with prior infection that has resolved per local institutions' requirements and screening guidance are eligible
* QTc Fridericia (QTcF) \> 470 ms
* Clinically significant cardiac disease, such as ventricular arrhythmia requiring therapy, uncontrolled hypertension or any history of symptomatic congestive heart failure (CHF)

Primary outcomes:
measure: Progression-free survival (PFS) by BICR
timeFrame: Up to 2.5 years
measure: Overall survival
timeFrame: Up to 3.5 years
Secondary outcomes:
measure: Confirmed objective response rate (ORR) by BICR
timeFrame: Up to 2.5 years
measure: Duration of response (DOR) by BICR
timeFrame: Up to 2.5 years
measure: PFS per Investigator assessment
timeFrame: Up to 2.5 years
measure: Confirmed ORR per Investigator assessment
timeFrame: Up to 2.5 years
measure: DOR per Investigator assessment
timeFrame: Up to 2.5 years
measure: Assessment of Contribution of Components based on Progression-free Survival (PFS) by BICR
timeFrame: Up to 2.5 years
measure: Assessment of Contribution of Components based on Overall Survival
timeFrame: Up to 3.5 years
measure: Incidence of adverse events
timeFrame: Up to 2 years
measure: Incidence of clinical laboratory abnormalities
timeFrame: Up to 2 years
measure: Health-related quality of life (HRQoL) as assessed by the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (core cancer questionnaire) C30 (QLQ-C30)
timeFrame: Up to 2.5 years
measure: HRQoL as assessed by the EORTC Quality of Life Questionnaire (oesophago-gastric module) OG25 (QLQ-OG25)
timeFrame: Up to 2.5 years
measure: HRQoL as assessed by the EuroQol 5-dimensions 5-levels (EQ-5D-5L) questionnaire
timeFrame: Up to 2.5 years
measure: Serum concentration of zanidatamab and tislelizumab
timeFrame: Up to 2 years
measure: Incidence of anti-drug antibodies (ADAs)
timeFrame: Up to 2 years
Other outcomes:
Locations:
city: Buenos Aires
country: Argentina
facility: Hospital de Gastroenterología Dr Bonorino Udaondo
city: Buenos Aires
country: Argentina
facility: Hospital Italiano de Buenos Aires
city: Ciudad Autónoma de Buenos Aires
country: Argentina
facility: Instituto de Investigaciones Metabólicas - IDIM
city: Córdoba
country: Argentina
facility: Fundación Centro de Medicina Nuclear y Molecular ER
city: Córdoba
country: Argentina
facility: Centro Médico Privado CEMAIC
city: Pergamino
country: Argentina
facility: Centro de Investigación Pergamino S.A.
city: Viedma
country: Argentina
facility: Centro de Investigación Clínica - Clínica Viedma
city: Bedford Park
country: Australia
facility: Flinders Medical Centre
city: Heidelberg
country: Australia
facility: Austin Health
city: Liverpool
country: Australia
facility: Liverpool Hospital
city: Murdoch
country: Australia
facility: Fiona Stanley Hospital
city: Bonheiden
country: Belgium
facility: Imelda VZW
city: Brussels
country: Belgium
facility: Cliniques Universitaires Saint-Luc
city: Gent
country: Belgium
facility: UZ Gent
city: Leuven
country: Belgium
facility: UZ Leuven
city: Liège
country: Belgium
facility: CHU de Liège
city: Barretos
country: Brazil
facility: Centro Integrado de Pesquisa - CIP
city: Barretos
country: Brazil
facility: Fundação Pio XII Hospital de Câncer de Barretos
city: Belo Horizonte
country: Brazil
facility: Cenantron - Centro Avancado de Tratamento Oncologico Ltda
city: Brasília
country: Brazil
facility: Centro de Pesquisas Clínicas/Fundação Doutor Amaral Carvalho
city: Fortaleza
country: Brazil
facility: Instituto Do Câncer Do Ceará ICC
city: Porto Alegre
country: Brazil
facility: Hospital de Clinicas de Porto Alegre (HCPA) - PPDS
city: Porto Alegre
country: Brazil
facility: Irmandade Da Santa Casa de Misericordia de Porto Alegre
city: Porto Alegre
country: Brazil
facility: Hospital Nossa Senhora Da Conceição
city: Santo André
country: Brazil
facility: Núcleo de Pesquisa Clínica da Rede São Camilo
city: Sorocaba
country: Brazil
facility: Instituto de Oncologia de Sorocaba
city: São Paulo
country: Brazil
facility: Instituto do Cancer do Estado de São Paulo ICESP
city: Toronto
country: Canada
facility: Princess Margaret Cancer Centre
city: Santiago
country: Chile
facility: Centro Internacional de Estudios Clinicos CIEC
state: Region Metropolitan
city: Providencia
country: Chile
facility: Fundación Arturo López Pérez (FALP) - PPDS
state: Región-Metropolitana De Santiago
city: Providencia
country: Chile
facility: Centro de Estudios Clínicos SAGA SpA
city: Santiago
country: Chile
facility: Sociedad Oncovida S.A
city: Santiago
country: Chile
facility: Icegclinic
city: Santiago
country: Chile
facility: BIOCINETIC SpA
city: Temuco
country: Chile
facility: Sociedad de Investigaciones Medicas Limitada
city: Beijing
country: China
facility: Beijing Chao-Yang Hospital, Capital Medical University
city: Beijing
country: China
facility: Cancer Hospital Chinese Academy of Medical Sciences
city: Beijing
country: China
facility: Beijing Cancer Hospital
city: Beijing
country: China
facility: Peking University Third Hospital
city: Beijing
country: China
facility: Beijing Luhe Hospital, Capital Medical University
city: Bengbu
country: China
facility: The First Affiliated Hospital of Bengbu Medical College
city: Changsha
country: China
facility: Hunan Cancer Hospital
city: Changzhi
country: China
facility: Changzhi People's Hospital
city: Changzhou
country: China
facility: Changzhou First People's Hospital
city: Chengdu
country: China
facility: Sichuan Cancer Hospital & Institute
city: Fuzhou
country: China
facility: The First Affiliated Hospital of Fujian Medical University
city: Fuzhou
country: China
facility: Fujian Cancer Hospital
city: Guangzhou
country: China
facility: Guangdong Provincial People's Hospital
city: Guangzhou
country: China
facility: The Sixth Affiliated Hospital of Sun Yat-sen University
city: Haikou
country: China
facility: Hainan General Hospital
city: Hangzhou
country: China
facility: The First Affiliated Hospital, College of Medicine, Zhejiang University
city: Hangzhou
country: China
facility: Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
city: Hangzhou
country: China
facility: Second Affiliated Hospital of Zhejiang University School of Medicine
city: Hangzhou
country: China
facility: Zhejiang Cancer Hospital
city: Harbin
country: China
facility: Harbin Medical University Cancer Hospital
city: Hefei
country: China
facility: Anhui Provincial Cancer Hospital
city: Hefei
country: China
facility: The Second Affiliated Hospital of Anhui Medical University
city: Hohhot
country: China
facility: Affiliated Hospital of Inner Mongolia Medical University
city: Jinan
country: China
facility: Shandong Cancer Hospital
city: Jinan
country: China
facility: Jinan Central Hospital
city: Kunming
country: China
facility: Yunnan Cancer Hospital
city: Lanzhou
country: China
facility: The First Hospital of Lanzhou University
city: Lanzhou
country: China
facility: Gansu Cancer Hospital
city: Nanchang
country: China
facility: The First Affiliated Hospital of Nanchang University
city: Nanjing
country: China
facility: Nanjing Drum Tower Hospital ,The Affiliated Hospital of Nanjing University Medical School
city: Qingdao
country: China
facility: The Affiliated Hospital of Qingdao University
city: Shanghai
country: China
facility: Ruijin hospital Shanghai Jiao Tong University School of Medicine
city: Shanghai
country: China
facility: Fudan University Affiliated Zhongshan Hospital
city: Shanghai
country: China
facility: Fudan University Shanghai Cancer Center
city: Shanghai
country: China
facility: Shanghai General Hospital
city: Shenyang
country: China
facility: Liaoning Cancer Hospital & Institute
city: Shijiazhuang
country: China
facility: The Fourth Hospital of Hebei Medical University
city: Tianjin
country: China
facility: Tianjin Medical University General Hospital
city: Tianjin
country: China
facility: Tianjin Medical University Cancer Institute & Hospital
city: Tonghua
country: China
facility: The Tonghua Central Hospital
city: Weihai
country: China
facility: Weihai Municipal Hospital
city: Wenzhou
country: China
facility: The First Affiliated Hospital of Wenzhou Medical University
city: Wuhan
country: China
facility: Union Hospital Tongji Medical College HuaZhong University of Science and Technology
city: Wuhan
country: China
facility: Hubei Cancer Hospital
city: Wuxi
country: China
facility: Affiliated Hospital of Jiangnan University
city: Xi'an
country: China
facility: First Affiliated Hospital of Xi 'an Jiaotong University
city: Xiamen
country: China
facility: The First Affiliated Hospital of Xiamen University
city: Yangzhou
country: China
facility: Northern Jiangsu People's Hospital
city: Zhengzhou
country: China
facility: Henan Cancer Hospital
city: Zhengzhou
country: China
facility: The First Affiliated Hospital of Zhengzhou University
city: Ürümqi
country: China
facility: Cancer Hospital affiliated to Xinjiang Medical University
city: Tallinn
country: Estonia
facility: North Estonia Medical Centre Foundation
city: Pessac
country: France
facility: CHU de Bordeaux - Hopital Haut Leveque
state: Gironde
city: Avignon
country: France
facility: Sainte-Catherine, Institut du Cancer Avignon Provence
city: Bordeaux
country: France
facility: EDOG - Institut Bergonie - PPDS
city: Dijon
country: France
facility: Universite de Bourgogne - Faculte de Medecine - IN
city: Grenoble
country: France
facility: Centre Hospitalier Universitaire Grenoble Alpes - Hopital Albert Michallon
city: Lyon
country: France
facility: Centre Léon Berard
city: Nantes
country: France
facility: EDOG Institut de Cancerologie de l'Ouest - PPDS
city: Poitiers
country: France
facility: CHRU de Poitiers La Miletrie
city: Rennes
country: France
facility: EDOG - Centre Eugene Marquis Centre Regional de Lutte Contre Le Cancer - PPDS
city: Saint-Priest-en-Jarez
country: France
facility: CHRU de Brest - Hopital Morvan
city: Toulouse
country: France
facility: Hôpital de Rangueil
city: Villejuif
country: France
facility: Hôpital Saint Antoine
city: Tbilisi
country: Georgia
facility: Research Institute of Clinical Medicine
city: Tbilisi
country: Georgia
facility: High Technology Hospital MedCenter Ltd
city: Frankfurt am Main
country: Germany
facility: Institut für Klinisch-Onkologische Forschung
state: Hessen
city: Athens
country: Greece
facility: Attikon University General Hospital
city: Thessaloniki
country: Greece
facility: Bioclinic Thessaloniki Oncology Department
city: Thessaloniki
country: Greece
facility: Agios Loucas Clinic SA
city: Thessaloniki
country: Greece
facility: Interbalkan Medical Center of Thessaloniki Oncology Department
city: Guatemala City
country: Guatemala
facility: Clinica Medica Especializada CELAN
city: Guatemala City
country: Guatemala
facility: Grupo Medico Angeles
city: Salcaja
country: Guatemala
facility: Centro Medico Integral de Cancerologia CEMIC
city: Bhubaneswar
country: India
facility: All India Institute of Medical Sciences, Bhubaneswar
city: Gurgaon
country: India
facility: Artemis Hospital
city: Hyderabad
country: India
facility: MNJ Institute of Oncology and Regional Cancer Centre
city: New Delhi
country: India
facility: Indraprastha Apollo Hospitals
city: Patna
country: India
facility: Regional Cancer Centre Indira Gandhi Institute of Medical Sciences
city: Vijayawada
country: India
facility: HCG City Cancer Center
city: Dublin
country: Ireland
facility: St James's Hospital
city: Bologna
country: Italy
facility: Azienda Ospedaliero Universitaria Di Bologna - Policlinico S Orsola Malpighi
city: Candiolo
country: Italy
facility: Fondazione del Piemonte per l'Oncologia (IRCCS)
city: Genova
country: Italy
facility: Ospedale Policlinico San Martino
city: Meldola
country: Italy
facility: Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori IRST - PPDS
city: Milano
country: Italy
facility: Ospedale San Raffaele S.r.l. - PPDS
city: Milano
country: Italy
facility: Istituto Nazionale Dei Tumori
city: Milano
country: Italy
facility: ASST Grande Ospedale Metropolitano Niguarda - Presidio Ospedaliero Ospedale Niguarda
city: Modena
country: Italy
facility: Azienda Ospedaliero Universitaria Di Modena Policlinico
city: Reggio Emilia
country: Italy
facility: Arcispedale Santa Maria Nuova
city: Rome
country: Italy
facility: Fondazione Policlinico Universitario A Gemelli
city: Verona
country: Italy
facility: Centro Ricerche Cliniche Di Verona
city: Vicenza
country: Italy
facility: Azienda ULSS 8 "Berica" - Ospedale San Bortolo
city: Gifu-Shi
country: Japan
facility: Gifu University Hospital
state: Gihu
city: Ota-shi
country: Japan
facility: Gunma Prefectural Cancer Center
state: Gunma
city: Akashi-shi
country: Japan
facility: Hyogo Cancer Center
state: Hyôgo
city: Kasama-Shi
country: Japan
facility: Ibaraki Prefectural Central Hospital
state: Ibaraki
city: Kita-Gun Miki-Cho
country: Japan
facility: Kagawa University Hospital
state: Kagawa
city: Yokohama-Shi Asahi-Ku
country: Japan
facility: Kanagawa Cancer Center
state: Kanagawa
city: Chuo-Ku
country: Japan
facility: Kumamoto University Hospital - Honjo-Kuhonji Campus A
state: Kumamoto
city: Sakyo-ku
country: Japan
facility: Kyoto University Hospital
state: Kyoto-shi
city: Osaki-Shi
country: Japan
facility: Osaki Citizen Hospital
state: Miyagi
city: Kurashiki-Shi
country: Japan
facility: Kurashiki Central Hospital
state: Okayama
city: Suita-Shi
country: Japan
facility: Osaka University Hospital
state: Osaka
city: Takatsuki-Shi
country: Japan
facility: Osaka Medical and Pharmaceutical University Hospital
state: Osaka
city: Chiba-Shi
country: Japan
facility: Chiba Cancer Center
state: Tiba
city: Kashiwa-shi
country: Japan
facility: National Cancer Center Hospital East
state: Tiba
city: Shinjuku-Ku
country: Japan
facility: Keio University Hospital
state: Tokyo
city: Chuo Ku
country: Japan
facility: National Cancer Center Hospital
city: Fukuoka-shi
country: Japan
facility: National Hospital Organization Kyushu Cancer Center
city: Ina
country: Japan
facility: Saitama Cancer Center
city: Matsuyama
country: Japan
facility: Shikoku Cancer Center
city: Osaka-sayama
country: Japan
facility: Kindai University Hospital
city: Osaka
country: Japan
facility: Osaka International Cancer Institute
city: Tokyo
country: Japan
facility: The Cancer Institute Hospital of Japanese Foundation For Cancer Research
city: Anyang-si
country: Korea, Republic of
facility: Hallym University Sacred Heart Hospital
city: Busan
country: Korea, Republic of
facility: Dong-A University Hospital
city: Daegu
country: Korea, Republic of
facility: Kyungpook National University Chilgok Hospital
city: Goyang-si
country: Korea, Republic of
facility: National Cancer Center
city: Incheon
country: Korea, Republic of
facility: Gachon University Gil Medical Center
city: Seongnam-si
country: Korea, Republic of
facility: CHA Bundang Medical Center, CHA University
city: Seongnam-si
country: Korea, Republic of
facility: Seoul National University Bundang Hospital
city: Seoul
country: Korea, Republic of
facility: Korea University Anam Hospital
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital
city: Seoul
country: Korea, Republic of
facility: The Catholic University of Korea, Seoul St. Mary's Hospital
city: Seoul
country: Korea, Republic of
facility: Kangbuk Samsung Hospital
city: Seoul
country: Korea, Republic of
facility: Severance Hospital Yonsei University Health System - PPDS
city: Seoul
country: Korea, Republic of
facility: Asan Medical Center
city: Seoul
country: Korea, Republic of
facility: Gangnam Severance Hospital, Yonsei University Health System
city: Seoul
country: Korea, Republic of
facility: Samsung Medical Center
city: Seoul
country: Korea, Republic of
facility: Korea University Guro Hospital
city: George Town
country: Malaysia
facility: Hospital Pulau Pinang
city: Kuching
country: Malaysia
facility: Sarawak General Hospital
city: Putrajaya
country: Malaysia
facility: National Cancer Institute ( Institut Kanser Negara)
city: Mexico City
country: Mexico
facility: Health Pharma Professional Research S.A de C.V.
city: Monterrey
country: Mexico
facility: Hospital Universitario Dr. Jose Eleuterio González
city: Oaxaca
country: Mexico
facility: Centro de Investigacion Clinica de Oaxaca
city: Eindhoven
country: Netherlands
facility: Catharina Hospital
city: Leiden
country: Netherlands
facility: Leids Universitair Medisch Centrum
city: Tilburg
country: Netherlands
facility: ETZ-Elisabeth
city: Warszawa
country: Poland
facility: Centrum Onkologii Instytut im. Marii Sklodowskiej-Curie
city: Łódź
country: Poland
facility: Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Lodzi
city: Almada
country: Portugal
facility: Hospital Garcia de Orta
city: Coimbra
country: Portugal
facility: Centro Hospitalar E Universitário de Coimbra EPE
city: Guimarães
country: Portugal
facility: Hospital Senhora da Oliveira - Guimaraes, E.P.E
city: Lisboa
country: Portugal
facility: Centro Hospitalar Lisboa Norte, E.P.E. - Hospital de Santa Maria
city: Matosinhos
country: Portugal
facility: Unidade Local de Saúde de Matosinhos SA
city: Porto
country: Portugal
facility: Centro Hospitalar do Porto EPE
city: Porto
country: Portugal
facility: Instituto Portugues de Oncologia Do Porto Francisco Gentil Epe - PPDS
city: București
country: Romania
facility: Fundeni Clinical Institute
city: Cluj-Napoca
country: Romania
facility: Prof Dr I Chiricuta Institute of Oncology - PPDS
city: Cluj-Napoca
country: Romania
facility: Medisprof SRL
city: Craiova
country: Romania
facility: Oncology Center Sfantul Nectarie
city: Belgrade
country: Serbia
facility: University Clinical Center of Serbia - PPDS
city: Belgrade
country: Serbia
facility: Clinical Hospital Center Bezanijska Kosa
city: Niš
country: Serbia
facility: University Clinical Center Nis
city: Sremska Kamenica
country: Serbia
facility: Oncology Institute of Vojvodina
city: Singapore
country: Singapore
facility: National Cancer Center Singapore
city: Pretoria
country: South Africa
facility: Wilgers Oncology Centre
city: Sabadell
country: Spain
facility: Corporacio Sanitaria Parc Tauli
state: Barcelona
city: Pamplona
country: Spain
facility: Complejo Hospitalario de Navarra
state: Navarra
city: Badalona
country: Spain
facility: Hospital Universitario Germans Trias i Pujol
city: Barcelona
country: Spain
facility: Hospital Universitario Vall d'Hebron - PPDS
city: Girona
country: Spain
facility: Hospital Universitari de Girona Dr Josep Trueta
city: L'Hospitalet de Llobregat
country: Spain
facility: Institut Català d'Oncologia (Hospital Duran y Reynals)
city: Madrid
country: Spain
facility: Hospital Universitario Ramon y Cajal
city: Madrid
country: Spain
facility: Hospital Universitario La Paz - PPDS
city: Málaga
country: Spain
facility: Hospital Regional Universitario de Malaga - Hospital General
city: Salamanca
country: Spain
facility: Complejo Asistencial Universitario de Salamanca - H. Clinico
city: Santander
country: Spain
facility: Hospital Universitario Marques de Valdecilla
city: Sevilla
country: Spain
facility: Hospital Universitario Virgen Macarena
city: Zaragoza
country: Spain
facility: Hospital Universitario Miguel Servet
city: Taichung
country: Taiwan
facility: China Medical University Hospital
city: Taipei
country: Taiwan
facility: Taipei Veterans General Hospital
city: Bangkok
country: Thailand
facility: Phramongkutklao Hospital
city: Hat Yai
country: Thailand
facility: Songklanagarind Hospital
city: Khon Kaen
country: Thailand
facility: Srinagarind Hospital, Khon Kaen University
city: Ankara
country: Turkey
facility: Hacettepe Universitesi Kanser Enstitusu
city: Edirne
country: Turkey
facility: Trakya University Medical Faculty
city: Izmir
country: Turkey
facility: Dokuz Eylul Universitesi
city: Seyhan
country: Turkey
facility: Acibadem Adana Hospital
city: Trabzon
country: Turkey
facility: Medical Park Trabzon Yildizli
city: Yenimahalle
country: Turkey
facility: Dr. Abdurrahman Yurtaslan Ankara Onkology Training and Research Hospital
city: Lutsk
country: Ukraine
facility: The Municipal Enterprise Volyn Regional Medical Oncology Centre of the Volyn Regional Council
city: Bristol
country: United Kingdom
facility: Bristol Haematology and Oncology Centre
city: Edinburgh
country: United Kingdom
facility: Western General Hospital Edinburgh - PPDS
city: Leeds
country: United Kingdom
facility: St James University Hospital
city: London
country: United Kingdom
facility: Guy's and St Thomas' NHS Foundation Trust - Guy's Hospital
city: London
country: United Kingdom
facility: Royal Marsden Hospital - London
city: London
country: United Kingdom
facility: Royal Marsden Hospital - Surrey
city: Peterborough
country: United Kingdom
facility: Edith Cavell Hospital
city: Sheffield
country: United Kingdom
facility: Weston Park Cancer Centre
Study officials:
References:
citation: Tabernero J, Shen L, Elimova E, Ku G, Liu T, Shitara K, Lin X, Boyken L, Li H, Grim J, Ajani J. HERIZON-GEA-01: Zanidatamab + chemo +/- tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinoma. Future Oncol. 2022 Sep;18(29):3255-3266. doi: 10.2217/fon-2022-0595. Epub 2022 Aug 24.